To include your compound in the COVID-19 Resource Center, submit it here.

Alexion reports Phase II CABG data

ALXN said that preliminary results of a Phase IIb study of its pexelizumab C5 inhibitor (5G1.1-SC) showed treatment

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE